Journal
HEPATOLOGY
Volume 52, Issue 6, Pages 2206-2215Publisher
WILEY
DOI: 10.1002/hep.24042
Keywords
-
Categories
Funding
- GSK
- Astellas and Gilead
Ask authors/readers for more resources
Insulin sensitizers are attractive candidate therapies for nonalcoholic steatohepatitis mainly because of the strong association between this disease and insulin resistance This review provides a critical overview of the mechanisms of action, clinical trial results, and safety issues of metformin and glitazones in nonalcoholic steatohepatitis It also highlights methodological challenges for trial design and proposes endpoints for future proof of principle, registrational, and postmarketing trials (HEPATOLOGY 2010,52 2206-2215)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available